Trial Profile
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Fostemsavir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Dec 2020 Results from two collective studies evaluating the impact of renal and hepatic impairment on Temsavir pharmacokinetics (PK) and safety following fostemsavir published in the Journal of Clinical Pharmacology.
- 08 Oct 2017 Results presented at the IDWeek 2017
- 07 Oct 2015 Status changed from not yet recruiting to completed as per ClinicalTrials.gov record.